Exelixis, Inc. is on the Cruelty Free Investing use of animals list because they use animals for drug testing and clinical trials.
The following press release mentions that the company conducts preclinical trials of their drugs on animals.
“Exelixis — with its expertise in the field of nuclear receptors and drug discovery — has identified a series of proprietary LXR agonist drug candidates that are highly potent, selective and efficacious in animal models of atherosclerosis. Exelixis’ lead compounds further display excellent pharmacokinetic profiles and a broad safety margin in multiple animal models.” Read the full document.
Exelixis, Inc. is a biopharmaceutical company, which engages in the developing and commercializing small molecule therapies for the treatment of cancer. Its brands include COMETRIQ and cobimetinib. The company focuses on their proprietary resources and development and commercialization of cabozantinib. Exelixis was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in South San Francisco, CA. [Source: MarketWatch]
Company Website: http://www.exelixis.com